BioCentury | Dec 2, 2020
Emerging Company Profile

Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets

Five years after Sofinnova Partners’ Antoine Papiernik first connected with Roche neurology veteran George Garibaldi, the pair have teamed up with Luigi Costa to launch orphan neurology company...
BioCentury | Nov 4, 2020

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

Novartis’ former CEO Joe Jimenez and NIBR head Mark Fishman believe that pairing digital technology with drug development in large underserved indications can provide a solid investment model and expedite...
BioCentury | Jun 19, 2020
Product Development

Hua shows sustained benefit in diabetics with glucokinase activator

Hua announced Phase III follow-up data showing its first-in-class diabetes therapy led to sustained HbA1c reductions at one year -- a long-term effect that EVP and CFO George Lin told BioCentury hasn’t been observed with...
BioCentury | Dec 19, 2019

Negative allosteric modulators of glutamate receptor subtypes mGluR2 and mGluR3

DISEASE CATEGORY: Neurology INDICATION: Depression Negative allosteric modulators of the glutamate receptor subtypes mGluR2 and mGluR3 could treat depression. Depression is characterized by reduced active coping mechanisms, intentional measures taken to lower stress, and more...
BioCentury | Dec 13, 2019

NanoDimension backs sight-restoring therapy developer Arctos in series A

Newly launched Arctos will use CHF8 million in series A money to conduct preclinical work on a vector-delivered technology it believes can restore eyesight in patients whose retinal cells have degenerated, rather than those whose...
BioCentury | Nov 13, 2019
Product Development

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by the limitations of previous compounds. Yet...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Sep 18, 2019
Distillery Therapeutics

SLC7A11 and mGluR5 identified as targets for hepatic alcoholic steatosis

DISEASE CATEGORY: Hepatic INDICATION: Liver disease Inhibiting SLC7A11, which excretes glutamate from cells, or the glutamate receptor mGluR5 could treat alcoholic steatosis of the liver. Patients with alcoholic fatty liver disease had elevated plasma levels...
BioCentury | Jan 11, 2019
Clinical News

Aevi's AEVI-001 misses in Phase II for children with ADHD

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) said AEVI-001 missed the primary endpoint in both Parts A and B of the Phase II ASCEND trial to treat ADHD in patients ages 6-17. The company plans to conduct...
BioCentury | Oct 3, 2018
Distillery Therapeutics


...PAM) of mGluR4 that could help treat catalepsy in PD. Optimization and testing in human mGluR4-expressing...
...CHO cells of a previously reported class of pyrazolopyridine-based PAMs yielded a compound that potentiated mGluR4-glutamate...
...small molecule mGlurR4 PAM, in preclinical testing for nicotine and drug addiction. TARGET/MARKER/PATHWAY: Metabotropic glutamate receptor subtype 4 (mGluR4; GRM4...
Items per page:
1 - 10 of 274